Pharmabiz
 

Teva Pharma launches generic Yaz tablets

JerusalemThursday, June 3, 2010, 08:00 Hrs  [IST]

Teva Pharmaceutical Industries Ltd. announced that it has commercially launched Gianvi (Drospirenone and Ethinyl Estradiol) tablets, the company's generic version of Bayer's Yaz tablets. Total sales of Yaz tablets were approximately $782 million in the United States, for the twelve months that ended December 31, 2009, based on IMS sales data. As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. As previously announced, Teva has the right to launch an authorized generic version of the product, supplied by Bayer, in July 2011. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients.

 
[Close]